Adverum Reports Three-Year Results of ADVM-022 in (OPTIC) Study for the Treatment of Wet Age-Related Macular Degeneration
Shots:
- The (OPTIC) study evaluates ADVM-022 in patients with wet AMD. The results showed a continuous & consistent therapeutic aflibercept expression level from ADVM-022 @3yrs. after a single IVT inj., no patients in 2x1011 vg/eye (2E11) required any topical corticosteroids
- 80% had baseline NAbs titers of <1:125 against AAV.7m8 & showed robust aflibercept protein expression & required fewer supplemental anti-VEGF inj., 81% reduction in mean annualized anti-VEGF inj. rate in patients with 2E11; 93% in NAbs titers <1:125; 70% in annualized rate of CST fluctuation with NAbs <1:125
- In Q3'22, the P-II study in wet AMD will begin with a 2E11 & 6E10 dose of ADVM-022 with preventive steroid regimens
Ref: Globenewswire| Image: Adverum
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
